1. Home
  2. ONC vs CQP Comparison

ONC vs CQP Comparison

Compare ONC & CQP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ONC
  • CQP
  • Stock Information
  • Founded
  • ONC 2010
  • CQP 2003
  • Country
  • ONC Switzerland
  • CQP United States
  • Employees
  • ONC N/A
  • CQP N/A
  • Industry
  • ONC Biotechnology: Pharmaceutical Preparations
  • CQP Oil/Gas Transmission
  • Sector
  • ONC Health Care
  • CQP Utilities
  • Exchange
  • ONC Nasdaq
  • CQP Nasdaq
  • Market Cap
  • ONC 26.9B
  • CQP 28.4B
  • IPO Year
  • ONC N/A
  • CQP 2007
  • Fundamental
  • Price
  • ONC $247.08
  • CQP $56.07
  • Analyst Decision
  • ONC Strong Buy
  • CQP Strong Sell
  • Analyst Count
  • ONC 7
  • CQP 5
  • Target Price
  • ONC $326.43
  • CQP $54.00
  • AVG Volume (30 Days)
  • ONC 314.8K
  • CQP 163.0K
  • Earning Date
  • ONC 08-06-2025
  • CQP 08-07-2025
  • Dividend Yield
  • ONC N/A
  • CQP 5.87%
  • EPS Growth
  • ONC N/A
  • CQP N/A
  • EPS
  • ONC N/A
  • CQP 4.16
  • Revenue
  • ONC $4,175,868,000.00
  • CQP $9,398,000,000.00
  • Revenue This Year
  • ONC $869.15
  • CQP $27.02
  • Revenue Next Year
  • ONC $19.07
  • CQP N/A
  • P/E Ratio
  • ONC N/A
  • CQP $13.41
  • Revenue Growth
  • ONC 51.16
  • CQP 3.94
  • 52 Week Low
  • ONC $141.31
  • CQP $47.00
  • 52 Week High
  • ONC $287.88
  • CQP $68.42
  • Technical
  • Relative Strength Index (RSI)
  • ONC N/A
  • CQP 39.58
  • Support Level
  • ONC N/A
  • CQP $55.87
  • Resistance Level
  • ONC N/A
  • CQP $59.00
  • Average True Range (ATR)
  • ONC 0.00
  • CQP 1.69
  • MACD
  • ONC 0.00
  • CQP -0.14
  • Stochastic Oscillator
  • ONC 0.00
  • CQP 8.33

About ONC BeiGene Ltd. American Depositary Shares

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

About CQP Cheniere Energy Partners LP Common Units

Cheniere Energy Partners is a liquified natural gas producer operating one facility in Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed- and variable-fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. The revenue generated through those activities is split with parent and operator Cheniere Energy.

Share on Social Networks: